Dagmar M. Ouweneel

Dagmar M. Ouweneel

Auto-generated profile, based on publicly available information

Dagmar M. Ouweneel

AMC Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in JACC
Verified
Journal Article
Closed access
DODagmar M. Ouweneel
Dagmar M. Ouweneel
EEErlend Eriksen
Erlend Eriksen
KSKrischan D. Sjauw
Krischan D. Sjauw
IDIvo M. van Dongen
Ivo M. van Dongen
AHAlexander Hirsch
Alexander Hirsch
Jose HenriquesJose Henriques
Jose Henriques

19 September 2016 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
DODagmar M. Ouweneel
Dagmar M. Ouweneel
JSJasper V. Schotborgh
Jasper V. Schotborgh
JLJacqueline Limpens
Jacqueline Limpens
KSKrischan D. Sjauw
Krischan D. Sjauw
AEA. E. Engström
A. E. Engström
Jose HenriquesJose Henriques
Jose Henriques
Purpose Veno-arterial extracorporeal life support (ECLS) is increasingly used in patients during cardiac arrest and cardiogenic shock, to support both cardiac and pulmonary function. We performed a systematic review and meta-analysis of cohort studies comparing mortality in patients treated with and without ECLS support in the setting of refractory cardiac arrest and cardiogenic shock complicating acute myocardial infarction. Methods We systematically searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the publisher subset of PubMed updated to December 2015. Thirteen studies were included of which nine included cardiac arrest patients (n = 3098) and four included patients with cardiogenic shock after acute myocardial infarction (n = 235). Data were pooled by a Mantel-Haenzel random effects model and heterogeneity was examined by the I 2 statistic. Results In cardiac arrest, the use of ECLS was associated with an absolute increase of 30 days survival of 13 % compared with patients in which ECLS was not used [95 % CI 6–20 %; p < 0.001; number needed to treat (NNT) 7.7] and a higher rate of favourable neurological outcome at 30 days (absolute risk difference 14 %; 95 % CI 7–20 %; p < 0.0001; NNT 7.1). Propensity matched analysis, including 5 studies and 438 patients (219 in both groups), showed similar results. In cardiogenic shock, ECLS showed a 33 % higher 30-day survival compared with IABP (95 % CI, 14–52 %; p < 0.001; NNT 13) but no difference when compared with TandemHeart/Impella (−3 %; 95 % CI −21 to 14 %; p = 0.70; NNH 33). Conclusions In cardiac arrest, the use of ECLS was associated with an increased survival rate as well as an increase in favourable neurological outcome. In the setting of cardiogenic shock there was an increased survival with ECLS compared with IABP.

7 July 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
HTHolger Thiele
Holger Thiele
AJAlexander Jobs
Alexander Jobs
DODagmar M Ouweneel
Dagmar M Ouweneel
JHJose P S Henriques
Jose P S Henriques
MSMelchior Seyfarth
Melchior Seyfarth
SWSuzanne de Waha
Suzanne de Waha
Evidence on the impact on clinical outcome of active mechanical circulatory support (MCS) devices in cardiogenic shock (CS) is scarce. This collaborative meta-analysis of randomized trials thus aims to investigate the efficacy and safety of percutanzeous active MCS vs. control in CS. Randomized trials comparing percutaneous active MCS to control in patients with CS were identified through searches of medical literature databases. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated to analyse the primary endpoint of 30-day mortality and device-related complications including bleeding and leg ischaemia. Mean differences (MD) were calculated for mean arterial pressure (MAP), cardiac index (CI), pulmonary capillary wedge pressure (PCWP), and arterial lactate. Four trials randomizing 148 patients to either TandemHeart™ or Impella® MCS (n = 77) vs. control (n = 71) were identified. In all four trials intra-aortic balloon pumping (IABP) served as control. There was no difference in 30-day mortality (RR 1.01, 95% CI 0.70 to 1.44, P = 0.98, I2 = 0%) for active MCS compared with control. Active MCS significantly increased MAP (MD 11.85 mmHg, 95% CI 3.39 to 20.31, P = 0.02, I2 = 32.7%) and decreased arterial lactate (MD − 1.36 mmol/L, 95% CI − 2.52 to − 0.19, I2 = 0%, P = 0.02) at comparable CI (MD 0.32, 95% CI − 0.24 to 0.87, P = 0.14, I2 = 44.1%) and PCWP (MD − 5.59, 95% −15.59 to 4.40, P = 0.14, I2 = 81.1%). No significant difference was observed in the incidence of leg ischaemia (RR 2.64, 95% CI 0.83 to 8.39, P = 0.10, I2 = 0%), whereas the rate of bleeding was significantly increased in MCS compared to IABP (RR 2.50, 95% CI 1.55 to 4.04, P < 0.001, I2 = 0%). Results of this collaborative meta-analysis do not support the unselected use of active MCS in patients with CS complicating AMI.

1 June 2018 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
VLValentine Léopold
Valentine Léopold
EGEtienne Gayat
Etienne Gayat
RPRomain Pirracchio
Romain Pirracchio
JSJindrich Spinar
Jindrich Spinar
JPJiri Parenica
Jiri Parenica
TCTahar Chouihed
Tahar Chouihed

1 January 2017 in JACC
Verified
Journal Article
Closed access
DODagmar M. Ouweneel
Dagmar M. Ouweneel
EEErlend Eriksen
Erlend Eriksen
MSMelchior Seyfarth
Melchior Seyfarth
JHJosé P.S. Henriques
José P.S. Henriques

3 May 2017 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
ACAlain Combes
Alain Combes
DBDan Brodie
Dan Brodie
Yih-Sharng ChenYih-Sharng Chen
Yih-Sharng Chen
EFEddy Fan
Eddy Fan
JHJosé P. S. Henriques
José P. S. Henriques
LPLaurent Papazian
Laurent Papazian